Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Parkinson disease

May 1, 2025 CD as API / Pharma applications

The revival of cyclodextrins as active pharmaceutical ingredients

Discovered in 1891, cyclodextrins, derived from starchy food, have found many applications in the cosmetic, agriculture, food and pharmaceutical industries

Continue reading

September 11, 2024 Drug delivery / Pharma applications

A new therapeutic approach to neurodegeneration? An old, known drug restarts flow of brain-cleaning fluids

On 15 August, 2024 Douglas Kelley, professor of mechanical engineering at the University of Rochester and his co-workers published that

Continue reading

January 15, 2024 CD as API / Drug delivery / Pharma applications

Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans

The elevated occurrence of debilitating neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s

Continue reading

January 11, 2024 Drug delivery / Pharma applications

Alpha-synuclein misfolding inhibitor minzasolmin dissolved in SBECD for treatment of Parkinson disease

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson’s disease and other synucleinopathies which is being

Continue reading

December 5, 2023 CD as API / Pharma applications

Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases

This work presents the most recent advances in the research and clinical use of HPβCD against Niemann–Pick disease, a congenital

Continue reading

September 5, 2023 Drug delivery / Pharma applications

Minzasolmin in SBECD solution for synuclein targeting in Parkinson disease treatment

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson’s disease and other synucleinopathies which is being

Continue reading

April 21, 2023 CD as API / Pharma applications

The review article ‘Molecular Mind Games’ describes the latest developments in cyclodextrin research for the treatment of brain disorders

The human brain is a complex and intricate network of cells and molecules that control every aspect of our behaviour

Continue reading

February 21, 2023 CD as API / Pharma applications

Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment

Parkinson-disease-patient-derived cells presented differences in their energetic profile, imbalanced proliferation, apoptosis, mitophagy, and a reduced differentiation efficiency to tyrosine hydroxylase

Continue reading

February 16, 2023 Drug delivery / Pharma applications

Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach

Neurodegeneration is characterized by progressive, disabling, and incurable neurological disorders with the massive loss of specific neurons. As one of

Continue reading

December 1, 2022 CD as API / Pharma applications

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

In this review, based on 250 references, the general chemical principles of direct cyclodextrin–protein interactions are summarized and highlighted, through

Continue reading

Posts pagination

1 2 Next Posts»

Recent Posts

  • Enhancing Linezolid Solubilization with β-Cyclodextrin Polymer Fractions of Different Molecula Weight
  • Book chapter: Functionalized cyclodextrins in drug delivery
  • β-Cyclodextrin-Complexed 1,8-Cineole Attenuates Motor Deficits and Preserves Tyrosine Hydroxylase Immunoreactivity in a Reserpine-Induced Mouse Model of Parkinsonism
  • Disruption of endosomal transport in cyclodextrin-mediated cytotoxicity
  • New Hungarian Medicine on the Horizon?

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (28)
  • Analysis (75)
  • CD as API (361)
  • CD derivatives (443)
  • Cosmetics and toilettry (55)
  • Diagnosis (15)
  • Drug delivery (832)
  • E-ducation (64)
  • Environmental (144)
  • Events (242)
  • Food (239)
  • Gene delivery (22)
  • Household products (6)
  • In Hungarian (4)
  • Life sciences (46)
  • Non-pharma applications (428)
  • Other industrial use (114)
  • Pharma applications (1,241)
  • Supramolecular systems (45)
  • Uncategorized (175)

Top Posts

  • Enhancing Linezolid Solubilization with β-Cyclodextrin Polymer Fractions of Different Molecula Weight
  • Rafael Holdings Announced Submission of New Drug Application to FDA for Trappsol®Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
  • Cyclodextrin Produced In situ: Rethinking Oat Milk Design for Better Performance
  • Arthur Lütringhaus, Godfather of catenanes was born 120 years ago
  • 16th Central European Symposium on Pharmaceutical Technology (CESPT 2027)
  • β-Cyclodextrin-Complexed 1,8-Cineole Attenuates Motor Deficits and Preserves Tyrosine Hydroxylase Immunoreactivity in a Reserpine-Induced Mouse Model of Parkinsonism
  • Disruption of endosomal transport in cyclodextrin-mediated cytotoxicity
  • Enantioseparation and molecular docking study of selected chiral pharmaceuticals on a commercialized phenylcarbamate-β-cyclodextrin column using polar organic mode
  • Special Issue 'Cyclodextrin-Based Nanomaterial For Drug Delivery and Biomedical Application'
  • Cyclopure Moves Towards Commercialization

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,470 other subscribers
Loading Comments...